KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at JMP Securities

JMP Securities started coverage on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research report report published on Friday, Marketbeat.com reports. The brokerage issued an outperform rating and a $19.00 price target on the specialty pharmaceutical company’s stock.

Several other brokerages have also weighed in on KALV. TD Cowen initiated coverage on shares of KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $30.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $23.80.

KalVista Pharmaceuticals Stock Up 1.6 %

Shares of KALV stock opened at $8.91 on Friday. The company has a 50-day moving average of $8.83 and a two-hundred day moving average of $10.90. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.01. As a group, analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,400 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $133,344.00. Following the sale, the chief executive officer now owns 266,598 shares of the company’s stock, valued at approximately $2,468,697.48. This trade represents a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the sale, the insider now directly owns 94,199 shares in the company, valued at approximately $872,282.74. The trade was a 7.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,291 shares of company stock valued at $304,086 over the last 90 days. 10.50% of the stock is owned by corporate insiders.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its position in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after acquiring an additional 2,043 shares during the last quarter. SG Americas Securities LLC grew its position in shares of KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares during the last quarter. Hennion & Walsh Asset Management Inc. purchased a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth approximately $634,000. JPMorgan Chase & Co. grew its position in shares of KalVista Pharmaceuticals by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock worth $262,000 after acquiring an additional 1,670 shares during the last quarter. Finally, Barclays PLC grew its position in shares of KalVista Pharmaceuticals by 418.5% during the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock worth $778,000 after acquiring an additional 54,257 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).